Latest / Stock Picking with Fexingo: Individual Equities, Research, and Building a Concentrated Portfolio / Pfizer's June Rally and the Dividend Catch-Up Trade
Transcript
- Lucas: So Pfizer is up almost seven percent over the last five days, and that's not just a bounce—that's a move that stands out when the S&P is up two percent and the Nasdaq is up three. Luna: Wait, seven percent? That's a huge week for a mega-cap pharma. What's driving it? Lucas: The headline is the dividend catch-up trade. Pfizer's been a laggard for years—the stock has been stuck below its pre-pandemic highs while the market has moved on. But with the Fed now signaling they might not hike in September—the odds just tumbled after that big July jobs miss—investors are scrambling for income, and suddenly Pfizer's yield starts to look very attractive. Luna: So it's a rate-driven rotation? Lower rates make dividend stocks more appealing? Lucas: Exactly. When you think rates might stay lower for longer, a stock yielding somewhere in the high single digits becomes a bond substitute. But there's a catch—a high yield can also be a red flag if the dividend isn't sustainable. That's why the catch-up trade isn't just about buying any high-yielder. You have to look under the hood. Luna: What's under Pfizer's hood? I know they've had some pipeline setbacks and the COVID revenue has collapsed. Lucas: Right, and that's why the market has been skeptical. The dividend is well-covered by earnings, though. The payout ratio is about forty percent, which is actually conservative for a big pharma. They've got a fortress balance sheet—over thirty billion in cash and investments. And they're not over-leveraged like some of the other dividend names people chase. Luna: But I feel like we've heard that before. What's the catalyst that's got people buying this week? Lucas: Partly it's the macro picture—the jobs report really shifted sentiment. But there's also a company-specific angle: they're starting to see some traction in their oncology pipeline, and there's chatter about a potential split or a spin-off of the consumer health business that could unlock value. Nothing official, but the market likes optionality. Luna: A spin-off would be a big deal. That's the kind of catalyst that can re-rate a stock. Lucas: It would. And it's worth noting that the market is rewarding Pfizer specifically while other defensives are lagging. Chevron is down three and a half percent this week, and that's interesting because energy stocks usually do well when rates are falling. But here, investors are clearly rotating into quality income—stability over cyclical exposure. Luna: So the rotation is kind of selective. It's not just 'buy yield.' It's 'buy yield with a clean balance sheet and a potential catalyst.' Lucas: That's the dividend catch-up trade in a nutshell. You're looking for a stock that's been left behind, but you want evidence that the yield is real and that there's a path to re-rating. Pfizer checks both boxes right now. Luna: How do you think about Pfizer in the context of a concentrated portfolio? Like, if you're only holding ten or twelve stocks, does a pharma name like this belong? Lucas: It's a fair question, and I think the answer is yes, but with a specific role. In a concentrated portfolio, you want a mix of growth and income. Pfizer can serve as your defensive anchor—the thing that pays you while you wait for the growth names to work. The dividend gives you a floor, and the payout ratio gives you confidence that floor isn't going to collapse. Luna: But there's always the risk of a yield trap, right? The stock could stay cheap for a long time. Lucas: That's the risk, and it's real. A high yield can be a value trap if the company is deteriorating. But with Pfizer, you have a management team that's committed to the dividend—they've been paying it for decades. And the balance sheet supports it. So the yield trap scenario is less about the dividend getting cut and more about the stock not re-rating. That's why you need that catalyst thesis. Luna: So it's not just a bond substitute. You're actually making a case for a turnaround. Lucas: That's the key. If you're just looking for yield, you can buy an ETF. The real opportunity is when you find a high-yielder that's also a turnaround story. And that's where the concentrated portfolio approach shines—you can do the work to identify those names and hold them with conviction. Luna: And speaking of doing the work, that's something we love to do here, and it's why we're able to have these conversations without ads. If our discussions have helped you think about investing differently, you can support the show at buy me a coffee dot com slash fexingo. It's a simple way to keep this podcast going, and we're grateful for anyone who finds value in it. Lucas: Yeah, that's right. We're listener-supported, so every bit helps. Now back to Pfizer—one thing I want to dig into is the payout ratio and how it compares to other big pharma names. Because not all dividends are created equal. Luna: How does Pfizer stack up against, say, Merck or Johnson & Johnson? Lucas: Merck has a payout ratio around fifty percent, J&J is in the forties, but they're both trading at higher multiples than Pfizer. Pfizer's P/E is significantly lower, which gives you more upside if the pipeline news starts to flow. It's a classic value plus income setup. Luna: And what about the dividend growth? Is Pfizer a dividend grower, or are we just talking about a static yield? Lucas: They've been increasing it for over a decade, though the increases have been modest recently. But if they execute on the pipeline, you could see that growth accelerate. That's the kind of thing that gets income investors excited. Luna: So, the dividend catch-up trade is really about finding a stock that's been left behind but has the fundamentals to catch up. Pfizer seems to hit that mark. But what are the risks? What could go wrong? Lucas: The biggest risk is that the pipeline disappoints again. They've had some high-profile failures in the past few years, and if the next big trial fails, the stock could sink back down. Also, if the Fed actually does hike in September—even though the odds have dropped—that would hurt all dividend stocks. And then there's the political risk around drug pricing, which never goes away. Luna: Right, drug pricing reform has been a cloud over pharma for years. But that's priced in to some extent, isn't it? Lucas: I think a lot of the pessimism is already reflected in the multiple. That's why the stock is so cheap. You're getting paid to take on those risks with a six percent yield while you wait. And if the market starts to believe in the pipeline, you get paid twice—dividends plus capital appreciation. Luna: That's an attractive risk-reward, but it requires patience. How long do you think this catch-up trade plays out? Lucas: If you look at historical patterns, these trades can take a year or two to fully play out. The market doesn't re-rate a stock overnight. But the nice thing about a dividend payer is that you're getting paid to wait. That's a luxury you don't have with a growth stock that's stuck in a rut. Luna: So it's a patient investor's game. And in a concentrated portfolio, you have to be willing to hold through the noise. Lucas: Exactly. And that's why we're talking about this now, as the market is rotating and people are looking for places to hide. Not all defensives are created equal, and Pfizer stands out as one that's both defensive and has a shot at meaningful upside. Luna: What would you say to someone who thinks Pfizer is just a falling knife? Lucas: I'd say look at the numbers. The dividend is covered, the balance sheet is strong, and the valuation is low. The knife might still be falling, but the risk-reward is skewed to the upside. You just have to have the conviction to hold it when the volatility hits. Luna: And that conviction comes from doing your homework. Which is exactly what this show is about. Lucas: Right. And if you want to do your own homework, start by looking at the free cash flow. That's the true measure of whether a dividend is sustainable. Pfizer generates a ton of it, and that's what gives me confidence. Luna: Good point. Free cash flow is the real test. So, to sum up, we're looking at Pfizer as a dividend catch-up play with a catalyst in the pipeline, a fortress balance sheet, and a reasonable payout ratio. It's not without risks, but the setup is compelling. Lucas: And that's the kind of analysis you can apply to any stock. Find the yield, check the coverage, and look for a reason the market is wrong. That's how you build a concentrated portfolio that works. Luna: Great. Thanks for joining us for this episode of Stock Picking with Fexingo. We'll be back with more ideas soon.